Diffuse macular edema in niacin-induced maculopathy may resolve with dosage decrease.
To report on a patient with niacin-induced cystic maculopathy that resolved with dosage decrease, not discontinuation, of niacin therapy for dyslipidemia. Retrospective case report. The patient was being followed for vision changes, but his niacin therapy was managed elsewhere. Results of the decrease in niacin dosage show clear evidence (with optical coherence tomography) of resolution of retinal edema. Our conclusion is that niacin's toxicity has a threshold, and dosage decrease below this threshold allows continuation of therapy at the lower dosage without clinically evident adverse effects on the retina.